Richard Bryce

5.8k citations

54 papers · 1.3k indexed · h-index 19

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
Cancer Research top 10%
- Cancer, Lipids, and Metabolism

Papers in ⓘ

Oncology 27
- HER2/EGFR in Cancer Research 18
- Cancer Treatment and Pharmacology 10
Cancer Research 13
- Cancer, Lipids, and Metabolism 8

Co-authors: Wen G. Jiang (11 shared papers)David F. Horrobin (7 shared papers)Robert E. Mansel (5 shared papers)Robert E. Mansel (2 shared papers)Gareth M. Watkins (2 shared papers)Anthony Douglas-Jones (1 shared paper)Sung‐Bae Kim (9 shared papers)Stephen Hiscox (4 shared papers)
Journals: Journal of Clinical Oncology (12 papers)Cancer Research (4 papers)Clinical Cancer Research (4 papers)Prostaglandins Leukotrienes and Essential Fatty Acids (4 papers)Future Oncology (3 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Richard Bryce

50 papers receiving 1.3k citations

Peers

Countries citing papers authored by Richard Bryce

Since Specialization

Citations

This map shows the geographic impact of Richard Bryce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Bryce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Bryce more than expected).

Fields of papers citing papers by Richard Bryce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Bryce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Bryce. The network helps show where Richard Bryce may publish in the future.

Co-authors

The 25 scholars most cited alongside Richard Bryce, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard Bryce Line = papers co-authored together Richard Bryce links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer JAMA Oncology ·Ahmad Awada, Rámón Colomer, Kenichi Inoue, Igor Bondarenko, Rajendra Badwe, Georgia Demetriou, Soo Chin Lee, Ajay Mehta, Sung‐Bae Kim, Thomas Bachelot, Chanchal Goswami, Suryanarayan V.S. Deo, Ron Bose, Alvin Wong, Feng Xu, Bin Yao, Richard Bryce, Lisa A. Carey	2016	217
2	Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes Prostaglandins Leukotrienes and Essential Fatty Acids ·Gareth M. Watkins, Anthony Douglas-Jones, Richard Bryce, Robert E. Mansel, Wen G. Jiang	2005	120
3	Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications Critical Reviews in Oncology/Hematology ·Wen G. Jiang, Richard Bryce, David F. Horrobin	1998	108
4	Regulation of Tight Junction Permeability and Occludin Expression by Polyunsaturated Fatty Acids Biochemical and Biophysical Research Communications ·Wen G. Jiang, Richard Bryce, David F. Horrobin, Robert E. Mansel	1998	101
5	Gamma linolenic acid with tamoxifen as primary therapy in breast cancer International Journal of Cancer ·F.S. Kenny, Sarah E. Pinder, Ian O. Ellis, Julia M.W. Gee, Robert I. Nicholson, Richard Bryce, John F.R. Robertson	2000	81
6	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. Journal of Clinical Oncology ·Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng, Ming‐Shen Dai, Sara A. Hurvitz, Sung‐Bae Kim, Beverly Moy, Suzette Delaloge, William J. Gradishar, Norikazu Masuda, Markéta Palácová, Maureen Trudeau, Johanna Mattson, Yoon Sim Yap, Richard Bryce, Bin Yao, Judith D. Bebchuk, Kiana Keyvanjah, Adam Brufsky, (unknown)	2019	73
7	Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of gamma linolenic acid in breast cancer cells Prostaglandins Leukotrienes and Essential Fatty Acids ·Wen G. Jiang, Andrew Redfern, Richard Bryce, Robert E. Mansel	2000	60
8	The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea Breast Cancer Research and Treatment ·Hope S. Rugo, Jack A. Di Palma, Debu Tripathy, Richard Bryce, Susan Moran, Elizabeth Olek, Linda D. Bosserman	2019	50
9	Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM) BMC Cancer ·Roman Hájek, Richard Bryce, Sunhee Ro, Barbara Klencke, Heinz Ludwig	2012	43
10	Neratinib (N) with or Without Temsirolimus (Tem) in Patients (Pts) with Non-Small Cell Lung Cancer (Nsclc) Carrying Her2 Somatic Mutations: an International Randomized Phase Ii Study Annals of Oncology ·Benjamin Besse, J.C. Soria, Bin Yao, Mark G. Kris, Bo H. Chao, Alexis B. Cortot, Julien Mazières, Mark A. Socinski, Leora Horn, Saiama N. Waqar, Fabrice Barlési, Jhanelle E. Gray, Denis Moro‐Sibilot, Ana B. Oton, Élisabeth Quoix, Alshad S. Lalani, Leanne McCulloch, Richard Bryce, Leena Gandhi	2014	38
11	Gamma Linolenic Acid Regulates Expression of Maspin and the Motility of Cancer Cells Biochemical and Biophysical Research Communications ·Wen G. Jiang, Stephen Hiscox, David F. Horrobin, Richard Bryce, Robert E. Mansel	1997	35
12	The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells British Journal of Cancer ·Wen G. Jiang, Stephen Hiscox, Richard Bryce, David F. Horrobin, R E Mansel	1998	32
13	Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma British journal of surgery ·C D Johnson, M. C. A. Puntis, N. Davidson, S. Todd, Richard Bryce	2001	29
14	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial Clinical Cancer Research ·Dhivya R. Sudhan, Luis J. Schwarz, Ángel Guerrero‐Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González-Ericsson, Melinda E. Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga	2018	26
15	The Effect of Fatty Acids and Analogues upon Intracellular Levels of Doxorubicin in Cells Displaying P-Glycoprotein Mediated Multidrug Resistance Journal of drug targeting ·Abedelnasser Abulrob, Malcolm Mason, Richard Bryce, Mark Gumbleton	2000	25
16	Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells Prostaglandins Leukotrienes and Essential Fatty Acids ·Wen G. Jiang, Richard Bryce, Robert E. Mansel	1997	23
17	Effect of dietary GLA+/?tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts International Journal of Cancer ·F.S. Kenny, Julia M.W. Gee, Robert I. Nicholson, Ian O. Ellis, Teresa Morris, Susan A. Watson, Richard Bryce, John F.R. Robertson	2001	19
18	γ-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells Prostaglandins Leukotrienes and Essential Fatty Acids ·Gareth M. Watkins, Tracey A. Martin, Richard Bryce, Robert E. Mansel, Wen G. Jiang	2005	19
19	Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids Clinical & Experimental Metastasis ·Wen G. Jiang, Sim K. Singhrao, Stephen Hiscox, Maurice B. Hallett, Richard Bryce, David F. Horrobin, Malcolm C.A. Puntis, Robert E. Mansel	1997	18
20	A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). Journal of Clinical Oncology ·Philippe Moreau, Antonio Palumbo, A. Keith Stewart, S. Vincent Rajkumar, Andrzej Jakubowiak, Kathleen G. Halka, Vesselina Goranova‐Marinova, Horia Bumbea, Kelly Pendergrass, Anca Roxana Lupu, Meletios Α. Dimopoulos, Albert Oriol Rocafiguera, J. G. Gandhi, Georgi Mihaylov, Tamás Masszi, J. Matous, Gustavo Fonseca, Richard Bryce, David S. Siegel	2011	18

About Richard Bryce

Richard Bryce is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Biochemistry and Biotechnology, having authored 54 papers that have together received 1.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (18 papers), Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (10 papers), Cancer, Lipids, and Metabolism (8 papers), Lung Cancer Treatments and Mutations (8 papers), Fatty Acid Research and Health (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Protein Degradation and Inhibitors (4 papers). The work is most often cited by research in Oncology (636 citations), Cancer Research (265 citations), Genetics (137 citations), Nutrition and Dietetics (172 citations) and Pulmonary and Respiratory Medicine (361 citations). Richard Bryce has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Wen G. Jiang, David F. Horrobin, Robert E. Mansel, Robert E. Mansel, Gareth M. Watkins, Anthony Douglas-Jones, Sung‐Bae Kim, Stephen Hiscox, F.S. Kenny and Ian O. Ellis. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Prostaglandins Leukotrienes and Essential Fatty Acids and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact